Daiwa Securities Group
TRML

Daiwa Securities Group’s Tourmaline Bio TRML Stock Holding History

Daiwa Securities Group’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-95
Closed -$5K – 1433
2025
Q3 		$5K Hold
95
– – ﹤0.01% 1209
2025
Q2 		$2K Hold
95
– – ﹤0.01% 1231
2025
Q1 		$1K Hold
95
– – ﹤0.01% 1257
2024
Q4 		$2K Hold
95
– – ﹤0.01% 1235
2024
Q3 		$2K Hold
95
– – ﹤0.01% 1236
2024
Q2 		$1K Hold
95
– – ﹤0.01% 1301
2024
Q1 		$2K Buy
+95
New +$3.35K ﹤0.01% 1278
2022
Q4 		– Sell
-12
Closed – – 1389
2022
Q3 		$0 Hold
12
– – ﹤0.01% 1398
2022
Q2 		$1K Hold
12
– – ﹤0.01% 1326
2022
Q1 		$1K Hold
12
– – ﹤0.01% 1344
2021
Q4 		$2K Buy
+12
New +$1.78K ﹤0.01% 1303

Daiwa Securities Group's TRML Position: Q4 2025 in Review

Daiwa Securities Group sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 95 shares — an estimated $5K sold.

Daiwa Securities Group first reported a position in TRML in Q4 2021 and held it in 11 quarters. The position peaked at $5K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

  • Daiwa Securities Group reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
  • Daiwa Securities Group sold 95 Tourmaline Bio shares in Q4 2025, an estimated $5K.
  • Daiwa Securities Group first reported a position in Tourmaline Bio in Q4 2021 and held it in 11 quarters.
  • Daiwa Securities Group's Tourmaline Bio position peaked at $5K in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Daiwa Securities Group's 13F filing for Q4 2025, filed 11 Feb 2026.